Replimune stock down after report on drug rejection (REPL)

Shares of Replimune (NASDAQ:REPL) plunged ~38% premarket after Stat News reported that Richard Pazdur, director of the FDA's Oncology Center of Excellence, directly intervened to cause the rejection of the company's lead asset, RP1, for melanoma treatment, despite internal agency support. This report clarifies the basis for the previously issued Complete Response Letter (CRL) and significantly undermines recent analyst optimism, including Cantor Fitzgerald's upgrade, which had anticipated a potential FDA reversal following the recent resignation of the FDA's Center for Biologics Evaluation and Research head.

Analysis

Replimune's (REPL) shares experienced a severe premarket decline of approximately 38%, directly linked to a Stat News report alleging that the FDA's head of oncology, Richard Pazdur, personally intervened to reject the company's lead drug, RP1. This new information provides critical, negative context to the Complete Response Letter (CRL) issued in late July for RP1's use in melanoma. The report indicates the rejection was a last-minute decision from the highest level of the FDA's cancer division, overriding internal support for the drug. This development materially undermines the recent bullish sentiment, including a Cantor Fitzgerald upgrade to 'Overweight', which was predicated on the theory that the resignation of a different FDA official, Vinay Prasad, could lead to a reversal of the CRL. The involvement of the Oncology Center of Excellence director suggests the regulatory hurdle for RP1 is more fundamental and less likely to be resolved by personnel changes, casting significant doubt on the asset's path to market.

Key Decisions for Investors

• Investors should recognize that the reported intervention by the FDA's top oncology regulator drastically increases the regulatory risk for RP1, making a near-term approval or a simple reversal of the CRL highly improbable.
• The bull thesis based on a potential FDA U-turn following a personnel change is now largely invalidated, warranting an immediate reassessment of any positions built on that specific catalyst.
• Given the ~38% premarket plunge, it is critical to re-evaluate REPL's valuation, as the prospects for its lead asset are now significantly more uncertain and likely subject to substantial delays or additional clinical trial requirements.